Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT; Bulletin Board: BLGTY) today announced that subsidiary DiagnosTear Ltd., which is engaged in the development of a diagnostic product for the treatment and monitoring of dry-eye syndrome, has obtained all the necessary permits from Sheba Medical Center Tel Hashomer Hospital to begin a clinical trial.
The company expects that the trial at the hospital to begin in a few days, and it is preparing to carry out the trial at another Israeli hospital. The company predicts that it will obtain the results from the trial during the fourth quarter of 2014. The trial's primary endpoint is to test the efficacy of the test developed by DiagnosTear on tears of patients and healthy people.
"The start of DiagnosTear's clinical trial is another milestone in the development process of one of the promising projects by Bio-Light's glaucoma and dry-eye cluster. 100 million patients a year suffer from dry-eye syndrome (and many more suffer from similar symptoms which require the same preliminary diagnosis), and need a major improvement in the level of diagnosis of the syndrome, a specific treatment for the cause of the syndrome, and monitoring of the treatment's success," said Bio-Light CEO Suzana Nahum-Zilberberg.
"The trial that the company is starting will study the effectiveness of the test developed by the company on human tears is another important stage in the development of the product, which has attracted great interest from leading companies and opinion-makers in the field," she added.
Published by Globes [online], Israel business news - www.globes-online.com - on February 10, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014